I am a board-certified medical oncologist dedicated to the care of patients with genitourinary malignancies. My clinical focus is the management of advanced cancers of the kidney and urinary tract, including bladder cancer. I work as part of a multidisciplinary team of Memorial Sloan Kettering surgeons, pathologists, radiation oncologists, and medical oncologists; and we collaborate closely to provide the best possible care to our patients and their families.
One of my main research interests is the development of new therapeutic strategies for patients with kidney and bladder cancers using novel, molecularly targeted medications. Through design and conduct of clinical trials, our team aims to improve upon the current standards of care. As an active member of the translational kidney cancer research program, I also collaborate closely with the basic scientists in Memorial Sloan Kettering’s Human Oncology and Pathogenesis Program (HOPP). Our principal goal is to reach a better understanding of the intricate genomic and molecular background of renal cell carcinoma. We investigate the impact these factors have on the clinical course of our patients and their response to the therapies we administer. Ultimately, our work in the laboratory aims to lay the foundation for a more individualized approach to our patients’ care.
In addition to my disease-focused efforts at Memorial Sloan Kettering’s Sydney Kimmel Center for Prostate and Urologic Cancers, I have an appointment to the Developmental Therapeutics Clinic, a dedicated program for early-phase drug development (“first-in-human” or “phase I clinical trials”) for patients with advanced cancers.
As a physician, I am a strong believer in patient education, shared decision-making, and the importance of recognizing the tremendous impact these cancers have on the day-to-day lives of our patients and their families.
I am fluent in German and English.
- Clinical Expertise: Genitourinary Malignancies, with a focus on kidney cancer (renal cell carcinoma) and bladder cancer. Early-phase drug development.
- Languages Spoken: English
- Education: MD, Albert-Ludwig University (Freiburg, Germany)
- Residencies: NewYork-Presbyterian Hospital/Weill Cornell Medical Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Martin H. Voss
- A Phase I Study of Debio1347 in Patients with Advanced Cancers Containing FGFR Alterations
- A Phase I/II Study of Pazopanib plus MK-3475 (Pembrolizumab) Immunotherapy in Patients with Previously Untreated, Inoperable Advanced Kidney Cancer
- A Phase I/II Study of Varlilumab plus Atezolizumab Immunotherapy in Patients with Advanced Kidney or Bladder Cancer
- A Phase II Study of Axitinib plus Dalantercept or Placebo for Patients with Metastatic Kidney Cancer
- A Pilot Study of Nivolumab Immunotherapy Given Before Surgery in Patients with High-Risk, Non-Metastatic Kidney Cancer
Clinical Trials Co-Investigated by Martin H. Voss
- A Phase I Study of CB-839 in Patients with Advanced Solid Tumors
- A Phase Ib Study of Ramucirumab plus LY2875358 in Patients with Advanced Cancer
- A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Cancer
- A Phase III Study of Atezolizumab Immunotherapy plus Bevacizumab versus Sunitinib Alone in Patients with Previously Untreated Renal Cell Cancer
- A Phase III Study of BMS-936558 Versus Everolimus in Patients with Advanced or Metastatic Renal Cell Carcinoma Who Received Prior Anti-Angiogenic Therapy
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more